Correction to Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial, (Lancet HIV (2017) 4 (e284–e294), (S2352301817300759), (10.1016/S2352-3018(17)30075-9));Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial

The Lancet HIV

Volumn 4, Issue 7, 2017, Pages e284-e294

  Aberg, Judith A ^a   Sponseller, Craig A ^b   Ward, Douglas J ^c   Kryzhanovski, Vladimir A ^d   Campbell, Stuart E ^e   Thompson, Melanie A ^f  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Kowa Pharmaceuticals of America   (United States)

^c Dupont Circle Physicians Group   (United States)

^d Lilly Corporate Center   (United States)

^e Kowa Research Institute   (United States)

^f AIDS Research Consortium of Atlanta   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; DARUNAVIR; HEMOGLOBIN A1C; LOPINAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; PRAVASTATIN; RITONAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HYPOCHOLESTEROLEMIC AGENT; PLACEBO; QUINOLINE DERIVATIVE;

ADULT; ANTIRETROVIRAL THERAPY; ARTERIOSCLEROSIS; ARTICLE; CD4 LYMPHOCYTE COUNT; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DIARRHEA; DIVERTICULITIS; DOUBLE BLIND PROCEDURE; DYSLIPIDEMIA; FEMALE; FOLLOW UP; GASTROENTERITIS; GLUCOSE METABOLISM; HEART ATRIUM SEPTUM DEFECT; HEART INFARCTION; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; MULTICENTER STUDY; MUSCLE BLEEDING; MYALGIA; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; RESPIRATORY TRACT INFECTION; THORAX PAIN; TRANSIENT ISCHEMIC ATTACK; TRIACYLGLYCEROL BLOOD LEVEL; VIRAL GASTROENTERITIS; ADOLESCENT; AGED; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; PUERTO RICO; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; DYSLIPIDEMIAS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PLACEBOS; PRAVASTATIN; PUERTO RICO; QUINOLINES; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 85017335415     PISSN: None     EISSN: 23523018     Source Type: Journal    
DOI: 10.1016/S2352-3018(17)30085-1     Document Type: Erratum

References (31)

1. Rodger, AJ, Lodwick, R, Schechter, M, et al. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS 27 (2013), 973–979.
2. 3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol 41 (2012), 433–445.
3. Maartens, G, Celum, C, Lewin, SR, HIV infection: epidemiology, pathogenesis, treatment, and prevention. Lancet 384 (2014), 258–271.
4. Hanna, DB, Ramaswamy, C, Kaplan, RC, et al. Trends in cardiovascular disease mortality among persons with HIV in New York City, 2001–2012. Clin Infect Dis 63 (2016), 1122–1129.
5. Freiberg, MS, Chang, CC, Kuller, LH, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 173 (2013), 614–622.
6. Paisible, AL, Chang, CC, So-Armah, KA, et al. HIV infection, cardiovascular disease risk factor profile, and risk for acute myocardial infarction. J Acquir Immune Defic Syndr 68 (2015), 209–216.
7. Buchacz, K, Baker, RK, Palella, FJ Jr, et al., for the HIV Outpatient Study Investigators. Disparities in prevalence of key chronic diseases by gender and race/ethnicity among antiretroviral-treated HIV-infected adults in the US. Antivir Ther 18 (2013), 65–75.
8. Myerson, M, Malvestutto, C, Aberg, JA, Management of lipid disorders in patients living with HIV. J Clin Pharmacol 55 (2015), 957–974.
9. Younas, M, Psomas, C, Reynes, J, Corbeau, P, Immune activation in the course of HIV-1 infection: causes, phenotypes and persistence under therapy. HIV Med 17 (2016), 89–105.
10. Jacobson, TA, Maki, KC, Orringer, CE, et al., on behalf of the NLA Expert Panel. National lipid association recommendations for patient-centered management of dyslipidemia: part 2. J Clin Lipidol 9:suppl (2015), S1–122.e1.
11. Stone, NJ, Robinson, J, Lichtenstein, AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129:suppl 2 (2014), S1–45.
12. Silverberg, MJ, Leyden, W, Hurley, L, et al. Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection. Ann Intern Med 150 (2009), 301–313.
13. Kowa Pharmaceuticals America, Inc and Eli Lilly and Company. LIVALO [package insert], October, 2013, Kowa Pharmaceuticals America, Inc, Montgomery, AL and Indianapolis, IN: Eli Lilly and Company.
14. Aberg, JA, Gallant, JE, Ghanem, KG, Emmanuel, P, Zingman, BS, Horberg, MA, Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 58 (2014), e1–34.
15. Aberg, JA, Lipid management in patients who have HIV and are receiving HIV therapy. Endocrinol Metab Clin North Am 38 (2009), 207–222.
16. Stender, S, Budinski, D, Gosho, M, Hounslow, N, Pitavastatin shows greater lipid-lowering efficacy over 12 weeks than pravastatin in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemia. Eur J Prev Cardiol 20 (2013), 40–53.
17. Morgan, RE, Campbell, SE, Suehira, K, Sponseller, CA, Yu, CY, Medlock, MM, Effects of steady-state lopinavir/ritonavir on the pharmacokinetics of pitavastatin in healthy adult volunteers. J Acquir Immune Defic Syndr 60 (2012), 158–164.
18. Janssen Pharmaceuticals. PREZISTA (darunavir). [package insert], October, 2011, Janssen Pharmaceuticals, Inc, Titusville, NJ.
19. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002), 3143–3421.
20. van Elteren, PH, On the combination of independent two-sample tests of Wilcoxon. Bull Internat Statist Inst 37 (1960), 351–361.
21. Sponseller, CA, Morgan, RE, Kryzhanovski, VA, Campbell, SE, Davidson, MH, Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial. Clin Ther 36 (2014), 1211–1222.
22. Malvestutto, CD, Ma, Q, Morse, GD, Underberg, JA, Aberg, JA, Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir. J Acquir Immune Defic Syndr 67 (2014), 390–396.
23. Gerber, JG, Rosenkranz, SL, Fichtenbaum, CJ, et al., for the AIDS Clinical Trials Group A5108 Team. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. J Acquir Immune Defic Syndr 39 (2005), 307–312.
24. Yu, CY, Campbell, SE, Sponseller, CA, Small, DS, Medlock, MM, Morgan, RE, Steady-state pharmacokinetics of darunavir/ritonavir and pitavastatin when co-administered to healthy adult volunteers. Clin Drug Investig 34 (2014), 475–482.
25. Nathan, B, Bayley, J, Waters, L, Post, FA, Cobicistat: a novel pharmacoenhancer for co-formulation with HIV protease and integrase inhibitors. Infect Dis Ther 2 (2013), 111–122.
26. Preiss, D, Seshasai, SR, Welsh, P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 305 (2011), 2556–2564.
27. Navarese, EP, Buffon, A, Andreotti, F, et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol 111 (2013), 1123–1130.
28. Galescu, O, Bhangoo, A, Ten, S, Insulin resistance, lipodystrophy and cardiometabolic syndrome in HIV/AIDS. Rev Endocr Metab Disord 14 (2013), 133–140.
29. Erlandson, KM, Jiang, Y, Debanne, SM, McComsey, GA, Rosuvastatin worsens insulin resistance in HIV-infected adults on antiretroviral therapy. Clin Infect Dis 61 (2015), 1566–1572.
30. Gumprecht, J, Gosho, M, Budinski, D, Hounslow, N, Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20–40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia. Diabetes Obes Metab 13 (2011), 1047–1055.
31. Vallejo-Vaz, AJ, Kondapally Seshasai, SR, Kurogi, K, et al. Effect of pitavastatin therapy on glucose, HbA1c and incident of diabetes mellitus: a meta-analysis of randomized controlled clinical trials in individuals without diabetes. Atherosclerosis 241 (2015), 409–418.